Fulgent Genetics (FLGT) Sets New 52-Week High at $6.41

Share on StockTwits

Shares of Fulgent Genetics Inc (NASDAQ:FLGT) hit a new 52-week high during trading on Wednesday . The stock traded as high as $6.41 and last traded at $6.29, with a volume of 300 shares. The stock had previously closed at $5.66.

Several analysts recently commented on FLGT shares. Zacks Investment Research downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. TheStreet raised Fulgent Genetics from a “d” rating to a “c-” rating in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $4.62.

The company has a market cap of $109.22 million, a PE ratio of -35.79 and a beta of 1.33.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings results on Thursday, February 28th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.02). Fulgent Genetics had a negative net margin of 21.02% and a negative return on equity of 6.96%. The firm had revenue of $5.68 million during the quarter, compared to analyst estimates of $5.90 million. As a group, equities analysts forecast that Fulgent Genetics Inc will post -0.13 EPS for the current year.

In other news, insider Ming Hsieh purchased 8,739 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were purchased at an average price of $4.95 per share, with a total value of $43,258.05. Following the purchase, the insider now directly owns 6,579,326 shares of the company’s stock, valued at approximately $32,567,663.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 58.80% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in FLGT. Financial Advisors LLC acquired a new stake in shares of Fulgent Genetics in the 4th quarter valued at about $35,000. Brown Advisory Inc. acquired a new stake in shares of Fulgent Genetics in the 4th quarter valued at about $46,000. Essex Investment Management Co. LLC acquired a new stake in shares of Fulgent Genetics in the 4th quarter valued at about $261,000. Finally, Old West Investment Management LLC raised its stake in shares of Fulgent Genetics by 8.5% in the 4th quarter. Old West Investment Management LLC now owns 434,454 shares of the company’s stock valued at $1,377,000 after purchasing an additional 34,140 shares during the period. 6.63% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Fulgent Genetics (FLGT) Sets New 52-Week High at $6.41” was posted by Zolmax and is the property of of Zolmax. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://zolmax.com/investing/fulgent-genetics-flgt-sets-new-52-week-high-at-6-41/3026223.html.

About Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

Featured Story: What is the yield curve?

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Critical Contrast: INDIVIOR PLC/S  and Its Rivals
Critical Contrast: INDIVIOR PLC/S and Its Rivals
Financial Review: Agilent Technologies  vs. PositiveID
Financial Review: Agilent Technologies vs. PositiveID
Zacks: Brokerages Expect Huntsman Co.  Will Announce Quarterly Sales of $2.10 Billion
Zacks: Brokerages Expect Huntsman Co. Will Announce Quarterly Sales of $2.10 Billion
Reviewing Vislink Technologies  and Its Rivals
Reviewing Vislink Technologies and Its Rivals
Zacks: Analysts Anticipate HCP, Inc.  Will Post Quarterly Sales of $439.80 Million
Zacks: Analysts Anticipate HCP, Inc. Will Post Quarterly Sales of $439.80 Million
BidaskClub Lowers Cerus  to Sell
BidaskClub Lowers Cerus to Sell


 
© 2006-2019 Zolmax.